CoChat

Factors influencing the levothyroxine dose in the hormone replacement therapy of primary hypothyroidism in adults

Open access
Caron, Philippe, Grunenwald, Solange, Persani, Luca, Borson-Chazot, Françoise, Leroy, Remy, Duntas, Leonidas · 2022 · Reviews in Endocrine and Metabolic Disorders

The DOI matches its Crossref record; 163 of the 165 references it cites were found in a registry or an index; 9 of the 132 sources its claims cite were checked for support.

Abstract

Levothyroxine (LT4) is a safe, effective means of hormone replacement therapy for hypothyroidism. Here, we review the pharmaceutical, pathophysiological and behavioural factors influencing the absorption, distribution, metabolism and excretion of LT4. Any factor that alters the state of the epithelium in the stomach or small intestine will reduce and/or slow absorption of LT4; these include ulcerative colitis, coeliac disease, bariatric surgery, Helicobacter pylori infection, food intolerance, gastritis, mineral supplements, dietary fibre, resins, and various drugs. Once in the circulation, LT4 is almost fully bound to plasma proteins. Although free T4 (FT4) and liothyronine concentrations are extensively buffered, it is possible that drug- or disorder-induced changes in plasma proteins levels can modify free hormone levels. The data on the clinical significance of genetic variants in deiodinase genes are contradictory, and wide-scale genotyping of hypothyroid patients is not currently justified. We developed a decision tree for the physician faced with an abnormally high thyroid-stimulating hormone (TSH) level in a patient reporting adequate compliance with the recommended LT4 dose. The physician should review medications, the medical history and the serum FT4 level and check for acute adrenal insufficiency, heterophilic anti-TSH antibodies, antibodies against gastric and intestinal components (gastric parietal cells, endomysium, and tissue transglutaminase 2), and Helicobacter pylori infection. The next step is an LT4 pharmacodynamic absorption test; poor LT4 absorption should prompt a consultation with a gastroenterologist and (depending on the findings) an increase in the LT4 dose level. An in-depth etiological investigation can reveal visceral disorders and, especially, digestive tract disorders.

Overview

CoChat Summary

## TL;DR

This review maps pharmaceutical, pathophysiological, and behavioural factors that alter levothyroxine (LT4) absorption, distribution, metabolism, and excretion, with most effects occurring at the absorption stage. It also gives a practical workup for patients with unexpectedly high TSH on apparently adequate LT4 dosing, emphasizing food/drug interactions, gastrointestinal disease, and LT4 absorption testing.

## Key findings

  • The literature search identified 741 potentially relevant publications; 140 were retrieved and 97 were reviewed.
  • Around 30% of patients fail to stably achieve the recommended TSH 0.4–4.0 mIU/L with a standard starting LT4 dose, typically 1.5–1.7 µg/kg/day in patients with residual thyroid function.
  • In the reviewed studies, the largest and most consistent effects were on absorption: food in the stomach, calcium/iron supplements, PPIs, bile acid sequestrants, sucralfate, fibre, and some gastrointestinal disorders were all reported to reduce LT4 absorption or increase LT4 dose needs.
  • Some interventions improved biochemical control or reduced dose requirements, including liquid LT4 in several settings and vitamin C, which in one study lowered TSH by about 70% at the same LT4 dose.

## Methods

  • Narrative review based on a PubMed search from January 1, 2000 to April 30, 2021, using combinations of LT4-/thyroid-related terms plus pharmacokinetic terms; only English-language publications and humans-focused clinical study filters were used.
  • Abstracts were screened for relevance; full texts were reviewed for eligible studies, and case reports, reviews, and editorials were excluded.
  • The authors classified influences on LT4 effectiveness into pharmaceutical, pathophysiological, and behavioural factors, and organized the discussion around ADME: absorption, distribution, metabolism, and excretion.

## Limitations

  • The paper states it searched only PubMed and screened only English-language publications.
  • Because this is a review, the evidence base is heterogeneous; the text repeatedly notes that findings are inconsistent for some factors, especially time of day of dosing, PPIs, and bariatric surgery.
  • Evident from the text: the review relies on studies with varied designs, small samples in some cases, and non-standardized LT4 absorption-test protocols, which limits direct comparison across studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s11154-021-09691-9

Cites

163 of 163 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 An overview of ADME processes for orally administered LT4 in the treatment of hypothyroidism
Fig. 1 An overview of ADME processes for orally administered LT4 in the treatment of hypothyroidismCC BY · PubMed Central
Fig. 2 Pathways and sites for the metabolism and excretion of LT4
Fig. 2 Pathways and sites for the metabolism and excretion of LT4CC BY · PubMed Central
Fig. 3 A summary of anatomic and functional changes that can reduce or slow the absorption of LT4 in the gastrointestinal tract
Fig. 3 A summary of anatomic and functional changes that can reduce or slow the absorption of LT4 in the gastrointestinal tractCC BY · PubMed Central
Fig. 4 A decision tree for patients with an abnormally high TSH level but who are reportedly taking the recommended, weight-adjusted dose of LT4
Fig. 4 A decision tree for patients with an abnormally high TSH level but who are reportedly taking the recommended, weight-adjusted dose of LT4CC BY · PubMed Central

Verification

Claims the paper makes

4 Valid · 2 Not valid · 87 Not checked · 19 Own results and interpretations

51 more claims

Create a free account to see all 112 claims and to verify the 123 references still open.

See all claims — free account
  • Probably not a substantial claim. 34
  • It may state two separate claims as one. 41

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 163 references

Research works printed but not linked: 1

  1. Medicines optimisation: The safe and effective use of medicines to enable the best possible outcomes. Accessed at 2015. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26180890.

Cited by

See all 66

Metadata

Authors
Caron, P., Grunenwald, S., Persani, L., Borson-Chazot, F., Leroy, R., & Duntas, L.
Affiliations
  • Centre Hospitalier Universitaire de Toulouse (FR)
  • University of Milan (IT)
  • National and Kapodistrian University of Athens (GR)
Corresponding author
Caron, Philippe
Venue
Reviews in Endocrine and Metabolic Disorders
Published
2021-10-20
Volume
23
Issue
3
Pages
463-483
ISSN
  • 1389-9155 (ISSN-L)
  • 1573-2606
OpenAlex
W3206952166
Cited by
53
References
165
Citations by year
2026: 12 · 2025: 14 · 2024: 12 · 2023: 12 · 2022: 3
FWCI
1.04
Type
journal article
Language
en
Open access
Licence
Locations
  • Reviews in Endocrine and Metabolic Disorders (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, cc-by)
Funders
merck kgaa
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
levothyroxine, primary hypothyroidism, hormone replacement therapy, levothyroxine dose, drug interactions, gastrointestinal diseases, gastric acid secretion, intestinal absorption, free thyroxine, thyroid-stimulating hormone, Helicobacter pylori infection, celiac disease, bariatric surgery, pharmacokinetics, pharmacodynamics
MeSH terms
Adult, Humans, Hypothyroidism, Thyrotropin, Thyroxine, Helicobacter pylori, Helicobacter Infections, Hormone Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Factors influencing the levothyroxine dose in the hormone replacement therapy of primary hypothyroidism in adults. https://app.cochat.ai/papers/10.1007/s11154-021-09691-9
The paper
Caron, P., Grunenwald, S., Persani, L., Borson-Chazot, F., Leroy, R., & Duntas, L. (2022). Factors influencing the levothyroxine dose in the hormone replacement therapy of primary hypothyroidism in adults. Reviews in Endocrine and Metabolic Disorders. https://doi.org/10.1007/s11154-021-09691-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.